INDEPENDENT STUDY OF OVARIAN CANCER CTCS HARVESTED BY THE PARSORTIX SYSTEM HIGHLIGHTS POTENTIAL TO PREDICT PROGRESSION FREE SURVIVAL FOR DRUG TRIALS The study investigated 123 metastatic ovarian ...
NuCana plc has initiated an expansion study of its anti-cancer drug NUC-7738 combined with pembrolizumab for patients with melanoma resistant to PD-1 inhibitors, with initial data expected in Q4 2025 ...
GUILFORD, SURREY AND PLYMOUTH MEETING, PA / ACCESS Newswire / November 5, 2025 / CELLBXHEALTH plc (AIM:CLBX)(OTCQX:ANPCY), a global leader in circulating tumour cell (CTC) intelligence, announces the ...
Morria Biopharmaceuticals Plc Announces Positive Clinical Results for MRX-4 in its Phase II Clinical Study in Allergic Rhinitis Patients LONDON and NEW YORK, November 06, 2008 /PRNewswire/ -- Morria ...
Indivior Plc presents results from the phase 3 pivotal study of RBP-6000 buprenorphine monthly depot
* Indivior Plc - 24-week study met its primary and key secondary endpoints for both dosage regimens of RBP-6000 * Indivior - Clinical data from phase 3 study also showed outcomes with RBP-6000 are ...
We recently compiled a list of the Top 10 Medical AI Stocks on Wall Street’s Radar. In this article, we are going to take a look at where Medtronic plc (NYSE:MDT) stands against the other medical AI ...
Parsortix platform shown to be compatible with the Roche BenchMark ULTRA automated staining system, with initial study of three key drug targets: HER2 (breast), TROP2 (lung) and PSMA (prostate) Roche ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results